Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06290713 · ClinicalTrials.gov registry record · Phase 2

Vasodilator and Exercise Study for DMD (VASO-REx)

A Phase 2 study of Exercise and Duchenne Muscular Dystrophy, sponsored by University of Florida.

Recruiting
Registry status
Phase 2
Development phase
50
Enrollment target
1
Study location

NCT06290713 is a Phase 2 study of Exercise and Duchenne Muscular Dystrophy that is actively recruiting participants, run by University of Florida. The registered enrollment target is 50 participants, below the 8,910-participant average among 57 other Exercise trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06290713, a Phase 2 study of Exercise and Duchenne Muscular Dystrophy, is actively recruiting participants, sponsored by University of Florida.

RECRUITING
Registry status
Phase 2
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

Examining two strategies as potential adjuvant therapies for Duchenne muscular dystrophy (DMD); aerobic exercise training (to induce adaptations in skeletal muscle and improve cardiovascular health) and tadalafil, an FDA-approved vasodilator (to optimize blood flow and muscle perfusion which is impaired and often overlooked in DMD). Target: improved muscle function, vascular health, and DMD treatment.

Interventions

  • DRUG Placebo
  • OTHER Exercise Training
  • DRUG Tadalafil

Study Locations (1)

Florida

  • University of Florida Clinical and Translational Research Building - Gainesville

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2024-06-05
Est. Completion 2026-11
Phase Phase 2

Sponsor

University of Florida

1,106 total trials

What the Registry Record Tells You About NCT06290713

The ClinicalTrials.gov registry entry for NCT06290713 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 8,910-participant average among 57 other Exercise trials with a reported enrollment target (99% lower). The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.

The record links to 7 conditions, with Exercise appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT06290713 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT06290713 about?

NCT06290713 is a clinical study titled "Vasodilator and Exercise Study for DMD (VASO-REx)". Examining two strategies as potential adjuvant therapies for Duchenne muscular dystrophy (DMD); aerobic exercise training (to induce adaptations in skeletal muscle and improve cardiovascular health) and tadalafil, an FDA-approved vasodilator (to optimize blood flow and muscle perfusion which is impa...

What is the current status of trial NCT06290713?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2024-06-05. Estimated completion is 2026-11.

What conditions does trial NCT06290713 study?

This clinical trial studies the following conditions: Exercise, Duchenne Muscular Dystrophy, Muscular Dystrophy, Vasodilation, DMD.

What interventions are being tested in trial NCT06290713?

The interventions under investigation include: Placebo (DRUG), Exercise Training (OTHER), Tadalafil (DRUG).

Who is sponsoring clinical trial NCT06290713?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06290713 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Exercise

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.